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Introduction. Pancreas transplantation (PTx) is the only deﬁnitive intervention for type 1 diabetes. Medical advancements in
diabetes care have led to an aging PTx candidate pool. We report our experience with patients ≥50 years of age undergoing
PTx. Methods. We reviewed 136 consecutive PTx patients at our institution from 1996–2010; 17 were ≥50 years of age. We
evaluateddemographics,surgicalcomplications,acute rejection (AR) rates,nonsurgicalinfections,andsurvivaloutcomes.Results.
Demographicdatawassimilar(P>. 05)between groups,excludingage.Thetwogroups hadcomparablemajorandminorsurgical
complication rates (P = .10 and P = .25, resp.). The older group had a lower 1-year and overall AR rate (P = .04 and P = .03,
resp.). The incidence of non-surgical infections and overall patient and graft survival was similar between groups (P>. 05).
Conclusion. Older patients with type 1 diabetes are feasible candidates for PTx, as surgical morbidity, incidence of infections, and
AR rates are low.
1.Introduction
Pancreas transplantation remains the best intervention for
type 1 diabetes mellitus that reestablishes normoglycemia
without the need for insulin therapy. Improvements in the
physician’s armamentarium to reduce the development of
diabetic complications have lead to the emergence of a
healthieraging populationoftype 1diabeticsin need ofpan-
creas transplantation [1, 2]. Progress in surgical techniques,
critical care, and immunosuppressive medications have also
expanded the pool of transplant candidates to include a
signiﬁcant proportion of patients over the age of 50 [3].
Despite continued improvements in the ﬁeld of trans-
plantation, pancreas transplantation has the highest mor-
bidity of all routinely performed abdominal solid organ
transplantation procedures [2, 4]. To further complicate
this procedure, the transplant pool often consists of older
diabetic patients, who will naturally have more preoperative
comorbiditiesthan their younger counterparts. Thus, weigh-
ingtheriskofthepancreastransplantationprocedureagainst
thebeneﬁtofinsulinindependencehasbeendebatable[5,6].
Salvalaggio et al. demonstrated a lower mortality in patients
receiving pancreas transplants, regardless of age, than those
remaining on the waiting list, even with older (45 years or
older) donors, compared to remaining on the waiting list
[7].
Many institutions have placed age limitations on poten-
tial pancreas transplant recipients, considering age a risk
factor for inferior outcomes. In one study patients 50 years
of age or older had a higher incidence of graft thromboses
and bleeding requiring re-exploration, as well as a higher
incidence of pulmonary infections [6]. Other studies have
shown a lower patient survival for older patients (45
years or older) undergoing pancreas transplantation [8, 9].
Additionally, Gruessner and Sutherland found that patients
older than 45 years of age had lower graft survival; however,
immunological graft loss decreased with increasing age [9].
Themean ageofpancreas transplant recipientscontinues
to increase; however, the data on older pancreas transplant
recipients remains limited. The intent of our retrospective
study was not only to demonstrate the feasibility of pancreas
transplantation in older recipients, but also to assess surgical2 Journal of Transplantation
morbidity, infectious risks, and overall outcomes of this
patient population.
2.Methods
From October 1996 to July 2010, 136 pancreas transplants
were performed in 131 patients. Of these 136 transplants,
92 were simultaneous pancreas-kidney (SPK) transplants,
37 were pancreas after kidney (PAK) transplants, and 7
were pancreas transplant alone (PTA). One hundred twelve
pancreas transplants were enterically drained, while the
remaining 24 had bladder drainage. All pancreas transplants
had systemic venous drainage. All patients were type 1
diabetics on insulin therapy preoperatively (C-peptide neg-
ative). We separated the recipients into two groups based on
age: those younger than 50 years of age and those 50 years of
age or greater.
Recipient baseline data reviewed included age, gender,
body mass index, age of diagnosis of diabetes, duration
of diabetes, preoperative hemodialysis requirement, comor-
bidities, serum albumin within 30 days of transplanta-
tion, incidence of Hepatitis C virus infection (HCV), and
cytomegalovirus (CMV) status. Donor and perioperative
data included donor age, donor CMV status, induction
therapy,coldischemiatime,andnumberofhumanleukocyte
antigen (HLA) mismatches.
Perioperative and postoperative parameters included
total operative time, estimated blood loss, length of hospital
stay, complications in the ﬁrst 30 days including graft
thrombosis, acute rejection rate, and incidence of delayed
graft function (deﬁned as the need for hemodialysis within
the ﬁrst week after transplant). Hemoglobin A1c (HgA1c)
levels were analyzed at 6 months, 1, 1.5, 2, and 3 years
posttransplant. Acute rejection episodes were deﬁned by
biopsy-proven results or empiric treatment with corticos-
teroids. Complications were graded using the modiﬁed
Clavien system, which categorizes surgical complications
based on the degree of intervention needed [10]. Minor
complications were classiﬁed as grade I-II, while major
complications were classiﬁed as grade III-V. Postsurgical
infectious complications included superﬁcial surgical site
infections, urinary tract infections, abscesses, and fever of
unknown origin. Gastrointestinal complications included
small bowel obstructions and ileus, while the urinary com-
plicationwas hematuria treated withurinary catheterization.
Hematological complications included acute blood loss
anemia and vessel thrombosis treated with anticoagulation.
The cardiovascular complications included postoperative
arrhythmias andacutemyocardial infarction. Re-exploration
was deﬁned as any operative procedure involving the
intraperitoneal or retroperitoneal space. Indications for re-
operation included open abdominal washouts, graft throm-
bosis, hernias/evisceration, major hemorrhage, anastomotic
site leak, and lysis of adhesions. All non-surgical infectious
complications were classiﬁed as bacterial, viral, or fungal.
Incidence of Posttransplant Lymphoproliferative Disease
(PTLD) was also recorded.
All potential transplant recipients were evaluated by a
multidisciplinary team. All potential recipients, irrespective
of age, undergo a rigorous preoperative work-up, including
cardiology clearance, a nuclear stress test, and an echocar-
diogram. All patients with unrevascularized coronary ar-
tery disease underwent revascularization procedures prior
to transplantation. Additionally, older recipients undergo
colonoscopy (age >50 years), mammography (women age
>40 years), and prostate-speciﬁc antigen testing (men age
>50 years) during the preoperative work-up. The follow-
ing criteria are considered contraindications to pancreas
transplantation at our institution: active infection, active
malignancy, active liver disease, unrevascularized coronary
artery disease, a history of noncompliance, active substance
abuse, or patients with signiﬁcant psychiatric disorders.
At our institution, induction therapy was not routinely
administered during pancreas transplantation until 2001.
Most patients received an IL-2 Receptor Antibody (IL-2RA),
while a small minority received rabbit Antithymocyte Glob-
ulin (ATG). The immunosuppression regimen consisted of
a calcineurin inhibitor (Tacrolimus or Cyclosporin), myco-
phenolate mofetil, and low-dose prednisone. Immunosup-
pression regimens and doses were similar for both younger
and older recipients. Calcineurin inhibitors were dosed
based on the same target trough levels for both groups. All
patients received prophylaxis with bactrim for 1 year and
valganciclovir for 6 months (3 months for donor negative/
recipient negative). All patients were routinely placed on
Aspirin therapy postoperatively.
Statistical analyses were performed using Graphpad
Prism software version 5.03 (GraphPad Software, Inc. La
Jolla, CA). All data are listed as mean ± standard deviation
(SD), unless otherwise speciﬁed. Categorical variables were
compared used chi-square test or Fisher’s exact test, while
continuous variables were compared using Student’s t-test
(two-tailed). Patient and death-censored graft survival rates
were calculated using the Kaplan-Meier method including
the log-rank test. A P-v a l u el e s st h a n. 0 5w a sc o n s i d e r e d
statistically signiﬁcant.
3.Results
Between October 1996 and July 2010, 131 patients under-
went 136 consecutive pancreas transplants at our institution.
Seventeen pancreas transplants (13%) were performed in
patients ≥50 years of age, while the remaining 119 pancreas
transplants (87%) were performed in patients <50 years of
age. The ≥50 years of age group consisted of 11 SPKs and
6 PAKs with a median age of 53 (range 50–61), while the
<5 0y e a r so fa g egr o u p sc o n s i s t e do f8 1S P K s ,3 1P A K s ,a n d7
PTAs with a median age of 37 (range 19–49).
Patient demographics and donor parameters are listed
in Table 1. As expected, the mean [±SD] recipient age was
signiﬁcantly higher in the ≥50 years of age group (54 ± 3.2
versus37 ±7.0, P<. 0001).However,therewasnodiﬀerence
between the two groups with respect to proportion of males,
body mass index, preoperative serum albumin, proportion
of patients on hemodialysis preoperatively, or proportion
of patients infected with HCV (P>. 05). Older recipients
developed type 1 diabetes at an older age (21 ± 9.2 years
of age) compared to younger recipients (13 ± 6.5 years,Journal of Transplantation 3
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Figure 1: Pancreas allograft function. The bar graph illustrates the
meanhemoglobinA1c(HgA1c)valuesforyoungerrecipients (blue)
and older recipients (red). The error bars represent the standard
deviation. The Y-axis is the percent glycosylated hemoglobin
present and the X- a x i si st h en u m b e ro fy e a r sp o s t t r a n s p l a n tf o r
each group. There was no signiﬁcant diﬀerence in HgA1c at 6
months, 1, 1.5, 2, and 3 years after transplant between the groups
(P>. 05).
P = .001). In addition older patients had a longer duration
of diabetes (33 ± 9.0 years versus 24 ± 6.8 years, resp.; P =
.0004).Additionally,olderrecipientsweremore likelytohave
a history of peripheral vascular disease (53% versus 27%,
P = .03) and/or coronary artery disease (47% versus 18%,
P = .006),butnothypertension (P = .85)orcerebrovascular
disease (P = .12). The proportion of enterically drained
pancreata, induction therapy, donor age, cold ischemia time,
andnumberofHLAmismatches wassimilarbetweenthetwo
groups (Table 1). The mean [±SD] follow-up time for the
twogroupswassimilar (5.9 ±4.5 years versus4.8 ±3.7years,
P = .48).
Table 2 lists the perioperative and postoperative parame-
ters.The totaloperativetime(P = .70)and lengthofhospital
stay was similar between the two groups (P = 1.0). The
older patients trended towards more blood loss (P = .06).
There was no diﬀerence between the groups with respect
to incidence of graft thrombosis (P = 1.0) and percentage
of patients experiencing a complication (P = .85) between
the two groups. The one year and overall acute rejection
rates, deﬁned by the number of patients experiencing at least
one episode of acute rejection in the given timeframe, were
signiﬁcantlylowerinthe ≥50yearsofagegroup(5.9%versus
30.2%, P = .04 and 11.8% versus 38.7%, P = .03, resp.).
The incidence of delayed graft function was similar between
the two groups (P = .54). Finally, there was no diﬀerence in
m e a nH g A 1 cv a l u e sa t6m o n t h s ,1 ,1 . 5 ,2 ,a n d3y e a r sa f t e r
transplant (P>. 05) (Figure 1).
The distribution of complications is listed in Table 3 for
both the <50 years of age group and the ≥50 years of age
group. There was no diﬀerence between the two groups in
all categories (P>. 05) except hematological complications
Table 1: Patient characteristics and donor parameters.
<50 years of age
N = 119
≥50 years of age
N = 17 P value
Male, n (%) 60 (50%) 11 (65%) .27
Recipient Age 37 ± 7.0 54 ± 3.2 <.0001
Body Mass Index
(kg/m2) 25.0 ± 5.0 26.1 ± 4.0 .30
Age at diagnosis of
type 1 DM (years) 13 ± 6.5 21 ± 9.2 .001
Duration of type 1
DM prior to
transplant (years)
24 ± 6.8 33 ± 9.0 .0004
Preoperative
Hemodialysis, n (%) 99 (83%) 13 (76%) .50
HCV, n (%) 5 (4%) 0 (0%) 1.0
Comorbidities:
Hypertension, n (%) 60 (50%) 9 (53%) .85
Peripheral Vascular
Disease, n (%) 32 (27%) 9 (53%) .03
Coronary Artery
Disease, n (%) 21 (18%) 8 (47%) .006
Cerebrovascular
Disease, n (%) 3 (3%) 2 (12%) .12
Preoperative serum
albumin (g/dl) 3.80 ± 0.58 3.86 ± 0.64 .98
CMV Status:
D+/R+, n (%) 39 (33%) 4 (24%)
D−/R+, n (%) 19 (16%) 3 (18%) .90
D+/R−, n (%) 31 (26%) 5 (29%)
D−/R−, n (%) 30 (25%) 5 (29%)
SPK, n (%) 81 (68%) 11 (65%)
PAK, n (%) 31 (26%) 6 (35%) .47
PTA, n (%) 7 (6%) 0 (0%)
Enteric Drainage, n
(%) 100 (84%) 16 (94%) .47
Induction therapy
used (yes), n (%) 65 (55%) 13 (77%) .12
Induction Agent:
None, n (%) 54 (45%) 4 (23%)
IL-2RA, n (%) 51 (43%) 10 (59%) .23
Antithymocyte
Globulin, n (%) 14 (12%) 3 (18%)
Donor Age (years) 30 ± 10.4 32 ± 10.7 .52
Pancreas Cold
Ischemia Time (hrs) 7.8 ± 3.1 7.2 ± 3.8 .52
HLA Mismatches 4 ± 1.2 4 ± 1.8 .41
Duration of
follow-up (years) 5.9 ± 4.5 4.8 ± 3.7 .48
DM = Diabetes mellitus, D = Donor, R = Recipient, IL-2RA = Interleukin-2
Receptor Antagonist, HLA = Human Leukocyte Antigen.
(P = .02). The rates of minor and major complications per
patient were not diﬀerent between the two groups (P = 10
and P = .25, resp.).4 Journal of Transplantation
Table 2: Perioperative and postoperative parameters.
<50 years of age
N = 119
≥50 years of age
N = 17 P value
Total operative time
(min) 283 ±92.9 271 ± 73.3. 7 0
Estimated blood loss
(ml) 571 ±510.1 730 ±399.2. 0 6
Length of Hospital
Stay (days) 12 ±9.11 1 ± 8.0. 6 1
Graft Thrombosis, n
(%) 13 (11%) 2 (12%) 1.0
No. of Patients
Experiencing a
Complication, n (%)
59 (50%) 8 (47%) .85
Delayed Graft
Function, n (%) 5/81 (6%) 1/11 (9%) .54
One Year Acute
Rejection Rate 30.2% 5.9% .04
Overall Acute
Rejection Rate 38.7% 11.8% .03
Table 3: Distribution of surgical complications.
Classiﬁcation <50 years of age
N = 66a
≥50 years of age
N = 10a P value
Infectious, n (%) 14 (21%) 1 (10%) .68
Gastrointestinal,
n (%) 4 (6%) 1 (10%) .52
Urinary, n (%) 1 (1%) 0 (0%) 1.0
Hematological, n (%) 6 (9%) 4 (40%) .02
Cardiovascular, n (%) 3 (5%) 1 (10%) .44
Radiological Drainage
of a Collection, n (%) 9 (14%) 1 (10%) 1.0
Re-operation, n (%) 29 (44%) 2 (20%) .19
Minor complications
per patient (mean) 0.14 0.35 .10
Major complications
per patient (mean) 0.41 0.24 .25
arefers to number of complications in each group.
Non-surgical infectious complications were categorized
based on infectious etiology in Table 4.T h ea v e r a g en u m b e r
of bacterial, viral, and fungal infections per patient in each
group was not signiﬁcantly diﬀerent (P>. 05). Furthermore,
the number of infections requiring hospitalizations was not
diﬀerent between the two groups (P>. 05). Finally, the
incidence of CMV infections and PTLD was also similar
between the two groups (P>. 05).
The overall patient survival was similar between the two
groups (Figure 2(a), log-rank P = .79). The 1-year patient
survival rates for the younger and older groups were 95%
and 100%, respectively. The 3- and 5-year patient survival
in the <50 years of age group was 93% and 90%, and 92%
and 82% in the ≥50 years of age group. The overall death-
censored graft survival was similar between the two groups
(Figure 2(b), log-rank P = .79). The 1 year death-censored
Table 4: Non-surgical infectious complications.
<50 years of age
N = 119
≥50 years of age
N = 17
P
value
Avg. No. of Bacterial
Infections/Patient 2.25 2.47 .72
Avg. No. of Viral
Infections/Patient 0.39 0.35 .88
Avg. No. of Fungal
Infections/Patient 0.13 0.06 .27
Avg. No. of Infections
Requiring
Hospitalization/Patient
0.86 1.18 .53
Incidence of CMV,
n (%) 22 (18%) 3 (18%) .93
PTLD, n (%) 1 (0.8%) 1 (5.9%) .24
CMV: Cytomegalovirus, PTLD: Posttransplant lymphoproliferative disor-
der.
graft survival for the <50 years of age and ≥50 years of age
groups was 89% and 88%, respectively. The 3- and 5-year
death-censored graft survival rates in the <50 years of age
group was 76% and 73%, and 80% and 70% in the ≥50 years
of age group.
4.Discussion
Pancreas transplantation remains the most eﬀective method
to achieve prolonged periods of normoglycemia. Our study
demonstratesthattype1diabetics50yearsofageoroldercan
successfully undergopancreas transplantation with favorable
outcomes. Additionally, these patients demonstrated a lower
acute rejection rate than younger patients, without an
increasedriskofinfectiouscomplications.Moreover,surgical
morbidity was notincreased in this olderpatient population.
The pool of pancreas transplant recipients has steadily
aged over the past decade [11]. As novel therapies for
type 1 diabetes continue to improve patient outcomes and
reduce complications, pancreas transplant candidates will
continue to increase in age and therefore have increasing
comorbidities. This, in combination with a high periopera-
tive complication rate (including re-exploration), compared
to other solid organ transplantation procedures, calls for
critical evaluation of suitable candidates for pancreas trans-
plantation [4, 12]. In Europe, the age limit for pancreas
transplantation candidates was originally set at 45 years
[13]. Over more than a decade, the maximum age limit
has increased, although no formal consensus exists. Several
studies demonstrated increased morbidity and mortality for
older pancreas transplant recipients and even advocated for
only transplanting younger patients [14, 15]. In one study, a
survival advantage for pancreas transplant candidates with
end-stage renal disease was seen in every age category,
except when patients were 50 years of age or older [16].
Nevertheless, more recent studies have demonstrated similar
outcomesforolderandyoungerpatientswithrespect tograft
and patient survival [2, 6].Journal of Transplantation 5
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Figure2:Kaplan-Meiersurvivalcurves.Theoverallpatientsurvival
isdepicted in(a),whilethedeath-censoredgraftsurvivalisdepicted
in (b). Survival curves were calculated using the Kaplan-Meier
method.Patientanddeath-censoredgraftsurvivalratesweresimilar
between the two groups (log-rank P = .78 & log-rank P = .79,
resp.). The median follow-up time was 5.1 years in the <50 years of
age group and 4.3 years in the ≥50 years of age group.
Inourcurrent study thenumber ofpatientsexperiencing
a major or minor complication in the two age groups was
not signiﬁcantly diﬀerent, despite increased comorbidities
in the older group. Hematologic complications were the
most frequent type of complication encountered in the 50
years of age or older group and this was the only type
of complication in which a signiﬁcant diﬀerence was seen
between the younger and older cohorts. This may be related
to the trend towards increased intraoperative blood loss in
the patients 50 years of age or greater. The most common
complication experienced in the less than 50 years of age
group were those requiring re-exploration. These results are
in contrast to Ablorsu et al. who found that patients 50
years of age or older had a higher incidence of bleeding
requiring re-exploration [6]. In another study by Freise
et al. older recipients (age 49 years or older) had similar
technical complication rates as recipients less than 49 years
of age [14]. Similarly, Schenkeret al. showed no diﬀerence in
complications requiring repeated laparotomy between older
and younger recipients [2].
A prominent cause of early graft loss cited in the
literature in pancreas transplantation has been vascular
thrombosis of the allograft [8]. In our study we found
that the ≥50 years of age group did not have an increased
incidence of graft thrombosis. Ablorsu et al. demonstrated
similar survival between older and younger patients; how-
ever, illustrated that patients aged 50 years or older had a
higherrateofgraftthrombosiscomparedtopatientsyounger
than 50 years of age [6]. In another study by Schenker and
colleagues, the venous graft thrombosis rates were similar
between older (14%) and younger recipients (11%) [2].
Immunological graft loss is an established cause of graft
failure. Our study shows a signiﬁcantly lower one-year
acute rejection rate in patients aged 50 years or older. This
couldbeexplainedbythedepressedimmunologicalresponse
associated with senescence [17]. Tesi et al. demonstrated in
a large series of kidney transplant recipients a lower rate of
acute rejection in patients 60 years of age or older, citing
senescence as a likely contributor [18]. Senescence in studies
such as this typically refers to patients aged 60 and older.
Nevertheless, similar to our study Gruessner and Sutherland
noticed a lower acute rejection rate in patients aged 45 years
or older, compared to younger patients [9]. Several other
studies, in contrast, did not see a signiﬁcant diﬀerence in the
acute rejection rates between older and younger recipients
[2, 6]. It is noteworthy that in this study, induction therapy
was used in almost 80% of older recipient transplants, while
almost 50% of the cases in the younger group had no
induction therapy administered.
In this study we noted similar postoperative infectious
complications between recipients less than 50 years of age
and those 50 years of age or older. Furthermore, the overall
infection rate over the lifespan of the allograft was similar
between the two groups, regarding bacterial, viral, and
fungal infections. It is well known that elderly patients
have a higher incidence of pulmonary infections following
surgery. Some contributors to this increased risk include de-
conditioning of respiratory musculature, poor nutritional
status, and impaired immune response associated with
senescence [17, 19]. In one study, older patients experienced
an increased incidence of chest and pulmonary infections
following pancreas transplantation [6] .W e ,h o w e v e r ,d i d
not see an increased risk of any type of infection in this
olderpopulation,includingCMVinfection.The incidenceof
PTLDwasover7timesgreaterintheolderagegroupthanthe
youngergroup;however,thiswasnotfoundtobestatistically
signiﬁcant. This is likely due to the small sample size of older
patients, and these patients should be evaluated regularly for
the development of PTLD.6 Journal of Transplantation
Patients 50 years of age or older experienced similar
short- and long-term graft and patient survival as patients
less than 50 years of age. The 1, 3, and 5 year patient survival
rates were 100%, 92%, and 82% in the patients aged ≥50
years of age and 95%, 93%, and 90% in patients younger
than 50 years of age, respectively. The death-censored graft
survival rates at 1, 3, and 5 years were 88%, 80%, and
70% in the older group and 89%, 76%, and 73% in the
younger group. The 1-year patient and graft survival rates
in the 50 years of age or older group is slightly better
than similar sized study (graft survival 88% versus 74% and
patient survival 100% versus 92%)[6]. On a larger scaled
metric, our graft and patient survival rates are comparable
to pancreas transplant recipients in the United States and
abroad [20, 21].
This study is not without limitations. This is a retrospec-
tiveanalysis from asingle institutionwithasmall sample size
and with the clear limitations of chart review. However, our
proportion of patients aged 50 or older (13%) is similar to
that found elsewhere in the United States (12%–15%) [9].
From 1996 to 2000, our recipients aged 50 years or older
compromised 7% of all pancreas transplant recipients. In
contrast, from 2001 to 2010, older recipients represented
almost 17% of all pancreas transplants at our institution.
Finally, theremay bea biasin the follow-up scheduleofolder
patients. Clinicians may follow these patients more stringent
and frequentthanyoungerpatients, which maycontributeto
the favorable outcomes.
This study demonstrates comparable outcomes of older
and younger recipients of pancreas allografts, and encourag-
ing outcomes of our older patients compared to previously
published literature reports. This is likely multifactorial in
nature. The evolution of more sophisticated immunosup-
pressive medications, coupled with innovation in surgical
techniques and advances in critical care may all contribute
to our results. Additionally, our older patient population is
carefully screened by medical, surgical, and cardiac consul-
tants prior to transplantation. All patients undergo revascu-
larization procedures before their consideration as potential
recipients. Preoperatively, our older patients demonstrated
excellent nutritional status, as evidenced by their preop-
erative serum albumin values. Meticulous donor selection
is an equally important contributor to our favorable older
recipient outcomes, including young donors (mean age 32
years) and short cold ischemia times (<8 hours). Finally,
olderrecipientsmay havebeen followed more rigorously and
possibly more frequently than younger patients, which may
contribute to the lower acute rejection rate.
5.Conclusions
In summary our data suggests that patients 50 years of age
or older are suitable candidates for pancreas transplantation
with excellent short- and long-term outcomes. In our expe-
rience older patients did not experience increased surgical
morbidity, infectious complications, or inferior patient and
graft survival rates compared to younger patients. These
patients may experience a lower acute rejection rate. With
careful patient selection and thorough medical assessment,
older patients should be considered potential candidates to
receive a pancreas allograft.
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